Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Nexgen Energy Ltd. Common Shares (NXE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Nexgen Energy Ltd. Common Shares — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.3 (market cap $12.58B), while Nexgen Energy Ltd. Common Shares trades at $8.84 (market cap $5.80B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 2.2× Nexgen Energy Ltd. Common Shares's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Nexgen Energy Ltd. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Nexgen Energy Ltd. Common Shares for 0 Days on average.
| HALO | NXE | |
|---|---|---|
Market Cap | $12.58B | $5.80B |
Volume | 2,179,278 | 6,795,738 |
Sector | Health | Energy |
52-Week High | $115.22 | $13.92 |
52-Week Low | $61.63 | $7.56 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $14.49B | $5.55B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Nexgen Energy Ltd. Common Shares
NexGen Energy develops uranium projects in Canada. Its main asset is the Rook I Project in Saskatchewan, which includes the Arrow uranium deposit.
Read more on NXE →
